Pharma
The pharma's Sandoz division will be handing commercialization of reSET, reSET-O and future therapies back to Pear over the course of a transition period.
The company will focus on digitally connecting its offerings, which are currently in use by more than 5,000 clinical trial sites and sponsors.
Because digital health is inherently different from other kinds of innovation like drug trials, the rules need to be rewritten, says Sunita Patolia, team lead for human-centered design at Partners HealthCare Pivot Labs.
Also: OptimizeRx delivers messaging through NewCrop's electronic prescription software; Novo Nordisk expands collaboration with Noom following strong pilot; Livongo signs its biggest payer yet.
Novartis has also announced that it will be opening a new AI innovation lab.
Medisafe and its partner's joint program enrolled "thousands" of cardiometabolic patients and posted adherence increases greater those of the Medisafe app alone.
Sanofi's deal with Abbott will be focusing on the diabetes space, while its deal with Happify will be looking at treating MS symptoms using a digital therapeutic.
Laura Shafner, chief strategy officer and founder of AiCure, discusses her experience within the industry.
This is the company's second platform-focused expansion within the last year.
Yesterday at the Voice of Healthcare Summit at Harvard Medical School, panelists discussed the lure of voice technology, its opportunities and the importance of keeping privacy front and center.